1. https://www.amgen.com/newsroom/press-releases/2022/12/amgen-presents-new-amg-133-phase-1-clinical-data-at-wcirdc-2022 2. Lu et al., 2021, Cell Reports Medicine 2, 100263,May 18, 2021 华人抗体协会是一个非营利、非政府的公益性组织,是第一...
参考文献:1. Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb; 6(2): 290-303. 专家简介 李勇...
参考文献: [1] Véniant MM, Lu SC, Atangan L, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. Publish...
Initiating Phase 2 Study in Early 2023 THOUSAND OAKS, Calif.,Dec. 1, 2022/PRNewswire/ --Amgen(NASDAQ:AMGN) today announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1...
[1]Amgen presents new AMG 133 phase 1 clinical data at WCIRDC 2022 . Retrieved Dec 1, 2022. From网页链接 [2]Amgen Business Review Meeting. Retrieved Fe 8, 2022, from网页链接 @药明康德内容团队报道 免责声明:药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的,文中观点不代...
A new study has reported the phase I results of AMG 133 (also known as maridebart cafraglutide), which is a bispecific molecule consisting of a glucose-dependent insulinotropic peptide receptor (GIPR) antagonist antibody conjugated to two glucagon-like peptide 1 (GLP1) agonists. The researchers...
Maridebartcafraglutide有望⽤于肥胖的研究[1][2]。REFERENCES[1].BloomgardenZT.The2023WCIRDC:Obesity[J].JournalofDiabetes,2024,16(4).[2].VéniantMM,etal.AGIPRantagonistconjugatedtoGLP-1analoguespromotesweightlosswithimprovedmetabolicparametersinpreclinicalandphase1settings.NatMetab.2024Feb;6(2):290-...
2月 5 日,安进(Amgen)的研究人员在 Nature Metabolism 期刊发表了题为:A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings 的研究论文,文中表示,安进开发的双特异性分子 AMG 133 每 4 周一剂注射,在第 3 次注射后体...
参考文献:1. Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb; 6(2): 290-303. 专家简介 李勇 复旦大学医学院内科学教授 ...
参考文献:1. Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb; 6(2): 290-303. 专家简介 李勇 复旦大学医学院内科学教授 ...